Oncology billing
Most claims describe what a patient received. An oncology claim also has to describe what they did not. Since July 2023 a separately payable single-dose-container drug must carry either modifier JW, naming on its own line the units discarded, or modifier JZ, attesting that there were none -- a positive statement, on every claim, about product that never reached the patient.
- JW reports discarded units on a second line; JZ attests there were none
- The discarded amount must also be recorded in the patient's medical record
- Where the billing unit covers both the dose and the waste, JW is not permitted and JZ applies
- Only one initial administration service is reported per encounter, absent separate access sites
This is an educational guide to how billing works for oncology — its workflow, coding, and payer considerations. It is general information, not a statement that US Medical Billing serves this specialty, and not billing, coding, or legal advice.
What makes oncology billing distinct
The drug and its administration are two claims lines for one act, and the drug line carries an obligation almost nothing else in medical billing does. The Medicare Claims Processing Manual explains that where a provider must discard the remainder of a single-dose container or single-use package after administering a dose, the programme pays for the discarded amount as well as the dose administered, up to the labelled amount -- and that since 2017 the JW modifier identifies those unused and discarded amounts.
Since July 2023 the obligation runs in both directions. The manual states that A/B MACs and DME MACs shall require the JZ modifier to attest that there were no amounts from single-dose containers unused and discarded for which JW would otherwise be required. So a claim now has to say one of two things about waste, and saying nothing is not among them. The manual also requires that discarded amounts be recorded in the patient's medical record, which makes the attestation a documentation obligation rather than a coding flag.
The definition of discarded is narrower than intuition suggests, and the arithmetic is unforgiving. The discarded amount is any amount not part of the prescribed dose and not intended to have a therapeutic effect -- generally the labelled amount on the container minus the dose given -- and the manual is explicit that amounts extracted from the vial, or required to be in it to administer the dose, are not counted as used if they were not intended for therapeutic effect. The manual's worked example is a hundred-unit container from which ninety-five units are given: ninety-five on one line, five on a second line with JW, both processed for payment.
There is a case where reporting the waste would be an overpayment, and the manual says so. Where the actual dose administered is less than a billing unit -- a seven-milligram dose from a vial whose billing unit is ten milligrams -- the single unit already pays for the whole ten, and a second line with JW is not permitted. From July 2023 that circumstance takes JZ instead. Getting this backwards is not a rounding difference; it is billing for something already paid for.
Around the drug sits an administration structure with its own arithmetic. The NCCI Policy Manual states that only one initial service code may be reported for a patient encounter, unless it is medically reasonable and necessary that the administrations occur at separate intravenous access sites. The administration codes are also valued to include the work and practice expense of the lowest-level established-patient office visit, so that visit code is not reported alongside them -- while a significant, separately identifiable office visit remains separately reportable with the appropriate modifier.
How oncology billing flows
The cycle runs on a regimen rather than an encounter: authorization, acquisition, administration and reconciliation each attach to a course of treatment.
Authorization for the regimen
Approval is sought for a plan -- agents, doses, cycles -- rather than a single visit, and a change to any of them can put subsequent administrations outside what was approved.
Common operational challenges
The recurring difficulties come from a claim that has to reconcile with a pharmacy, an inventory and a treatment plan at the same time.
Waste is a fact created at the bench
The number of units discarded is established during preparation, by pharmacy staff, in a system that may not be the billing system. If it does not travel, the claim cannot make the attestation the payer now requires.
Units are not vials
Every drug code has its own billing unit, and the claim reports units of measure rather than containers. A dose expressed in milligrams, a vial expressed in units, and a code expressed in something else again is where high-cost errors live.
Buying before being paid
Acquiring drugs and billing for them puts the practice's own money in the claim. A denial on a drug line is a loss of product, not only of revenue, which changes how quickly it has to be worked.
Approval that describes a plan, not a visit
Authorization attaches to a regimen. A dose reduction, an added agent or a delayed cycle can move the treatment outside the approval without anyone thinking of it as a billing event.
Documentation and coding considerations
The CPT code set is maintained by the American Medical Association; the notes below describe documentation and reporting considerations rather than reproduce any code descriptions.
The two-line structure for a discarded amount
The administered amount goes on one line with the drug's billing and payment code, no modifier, and the units administered. The discarded amount goes on a second line with the same code, the JW modifier, and the units discarded. Both lines are processed for payment.
The attestation when nothing was discarded
Since July 2023 the administered line carries the JZ modifier to attest there were no discarded amounts for which JW would otherwise have been required. It applies to separately payable Part B drugs described as supplied in single-dose containers or single-use packages under FDA-approved labeling.
Where JW is not permitted
Where the actual dose administered is less than the billing unit, the single unit already pays for the whole labelled amount, so a second JW line would be an overpayment. The manual states JW is not permitted when the billing unit is equal to or greater than the total actual dose plus the amount discarded; from July 2023 the JZ modifier is used instead.
Where the policy does not reach
The manual states that the modifiers are not appropriate for drugs from multiple-dose containers, and that the policy does not apply to drugs that are not separately payable -- packaged outpatient or ambulatory surgical centre drugs, or drugs administered in a federally qualified health centre or rural health clinic setting.
One initial administration service
The NCCI Policy Manual states that only one initial service code may be reported for a patient encounter unless it is medically reasonable and necessary that the administrations occur at separate intravenous access sites, in which case the associated modifiers apply. Flushing or irrigating an implanted vascular access port before or after administration is integral and not separately reportable.
Denial and rejection risks
On a high-cost drug line, a units error costs more than most whole encounters -- and the attestation errors are silent until a review finds them.
A drug line with no waste attestation
A separately payable single-dose-container drug reported with neither JW nor JZ does not carry the statement the payer requires. It is an incomplete claim rather than a debatable one.
JW used where the billing unit already covers the waste
Reporting a second line for the remainder of a vial whose billing unit is larger than the dose plus the waste produces payment for the same drug twice, which is the overpayment the manual describes rather than an aggressive interpretation.
Units taken from vials rather than from the code
Billing units are defined per code and per dosage, not per container. Units derived from the number of vials opened will not reconcile with the dose recorded, and on these codes the difference is large.
Two initial administration services
Reporting a second initial service without separate intravenous access sites and the associated modifier contradicts the manual's rule directly. Hydration given concurrently with chemotherapy is also not separately reportable.
A visit already inside the administration code
The drug and chemotherapy administration codes are valued to include the lowest-level established-patient office visit. Reporting that visit alongside them is denied; a significant, separately identifiable visit reported with the appropriate modifier is not.
Payer-process considerations
The drug side and the service side of an oncology claim answer to different policy machinery, and both move.
A published list of the codes that require it
CMS publishes the list of billing and payment codes that may require the JW and JZ modifiers, and the policy has been extended in stages -- including to billing suppliers who do not administer the drug. Checking the current list is part of the process rather than a one-off setup.
Setting decides whether the rules apply at all
Drug administration services reported by practitioners are office-setting services; the manual states they are not reported by providers for services furnished in a facility setting such as a hospital outpatient or emergency department, while hospital outpatient facilities may report them where appropriate.
Authorization against a regimen
Plans authorize a treatment plan, and increasingly review it against their own pathway policy. Changes to the plan are the moment to re-check the authorization, not the moment to submit the claim.
Commercial and Medicare Advantage variation
Commercial plans and Medicare Advantage plans set their own drug policies, may require a specific acquisition route, and administer their own waste-reporting rules. The federal policy describes Original Medicare.
Revenue-cycle checkpoints
The first three are about the drug line, which is where the money and the risk both concentrate.
- Capture the dose administered and the amount discarded at preparation, in the patient's medical record
- Attest on every separately payable single-dose-container drug line -- JW with the discarded units, or JZ where there were none
- Check whether the billing unit already covers the dose plus the waste before adding a JW line
- Derive billing units from the code's unit of measure and the dose, never from the number of vials
- Report one initial administration service per encounter unless separate access sites were medically necessary and documented
- Keep port flushing, concurrent hydration and the lowest-level visit off the administration claim
- Re-check the authorization whenever the regimen changes, not when the claim is built
- Reconcile drug revenue against drug cost line by line, because a units error here outweighs a visit
Related & connected
Services, tools, background reading and definitions that connect to the oncology revenue-cycle steps above.
Related services
Calculators & tools
- HCPCS code lookupThe Level II code set that carries drugs and biologicals, and their billing units.
- Prior authorization request checklistAssembling the clinical evidence for an authorization that describes a regimen.
- Contractual variance calculatorCompare expected against paid, which is how a drug-line shortfall is found.
From the Knowledge Base
- Medicare Part B drugs and biologicalsThe average sales price framework, HCPCS billing units and coverage rules the drug line sits inside.
- Matching authorized units to billed servicesKeeping what was approved and what was administered in step across a course of treatment.
- Underpayments and overpaymentsFinding a claim that paid but paid wrongly, which on these codes is worth finding quickly.
- Prior authorization for medicationsHow drug authorizations are requested and tracked, including for a multi-cycle plan.
Glossary
- HCPCS Level IIThe code set that carries drugs and biologicals, each with its own billing unit.
- National Drug CodeThe product identifier a drug claim may have to carry alongside its billing code.
- ModifierThe two-character code that here carries an attestation about product that was discarded.
- OverpaymentWhat a second waste line becomes when the billing unit already covered the discarded amount.
Frequently asked questions
What do the JW and JZ modifiers do?
They make a claim state what happened to the part of a single-dose container that was not given. The Claims Processing Manual requires JW to identify unused and discarded amounts of a drug or biological from a single-dose container or single-use package, reported on a second claim line with the same billing code and the number of units discarded. Since July 2023 it requires JZ on the administered line to attest that there were no such amounts. Between them there is no silent option: a separately payable single-dose-container drug line has to say one or the other.
How is the discarded amount calculated?
Generally as the labelled amount on the single-dose container, or containers where more than one is required, minus the dose administered. The manual defines the discarded amount as any amount that is not part of the prescribed dose and not intended to have a therapeutic effect in the patient, and adds that amounts extracted from the vial, or required to be in the vial to administer the prescribed dose, are not treated as used if they were not intended for therapeutic effect. Its example is a hundred-unit container from which ninety-five units are administered and five discarded: ninety-five on one line, five on a second line with JW, both processed for payment.
Is the discarded amount always billed on a second line?
No, and getting this wrong causes an overpayment. Where the actual dose administered is less than the billing unit, the single unit already pays for the whole labelled amount -- the manual's example is a seven-milligram dose from a vial whose billing unit represents ten milligrams, where the one unit is processed for payment of the full ten. Reporting a further unit with JW for the three milligrams discarded is not permitted, because it would be paid for twice. For dates of service from July 2023 the JZ modifier is used in that circumstance.
Do these rules apply to every drug a practice administers?
No. The manual states that the policy generally applies to drugs separately payable under Part B that are described as being supplied in a single-dose container or single-use package based on FDA-approved labeling, and that the modifiers are not appropriate for drugs from multiple-dose containers. It does not apply to drugs that are not separately payable, such as packaged outpatient or ambulatory surgical centre drugs, or to drugs administered in federally qualified health centre or rural health clinic settings. CMS publishes the list of codes that may require the modifiers.
If several drugs are infused in one visit, is each one an initial service?
No. The NCCI Policy Manual states that only one initial service code may be reported for a patient encounter, unless it is medically reasonable and necessary that the drug administrations occur at separate intravenous access sites -- in which case two initial services may be reported with the associated modifiers. Related rules follow the same logic: flushing or irrigating an implanted vascular access port before or after administration is integral to the administration, and hydration given concurrently with chemotherapy is not separately reportable.
Sources
Last reviewed July 31, 2026.
- Centers for Medicare & Medicaid Services (CMS)Medicare Claims Processing Manual (Pub. 100-04), Chapter 17 §40 Discarded Drugs and Biologicals -- the JW modifier and the two-line structure, the JZ attestation required from July 2023, the definition and calculation of the discarded amount, the worked examples, the circumstance in which JW is not permitted, and the drugs and settings the policy does not reach
- Centers for Medicare & Medicaid Services (CMS)JW modifier and JZ modifier policy -- the published list of billing and payment codes that may require the modifiers
- Centers for Medicare & Medicaid Services (CMS)National Correct Coding Initiative Policy Manual, Chapter XI (Medicine) section N -- chemotherapy administration: one initial service per encounter, the separate access site exception, the setting restriction, the office visit valued into the administration codes, port flushing as integral, and concurrent infusion and hydration
Ready to improve your revenue cycle?
Tell us about your practice and we’ll tell you where we would start.